文拉法辛对选择性5-羟色胺再摄取抑制剂治疗无显效的抑郁症患者的疗效和安全性的临床对照观察  

Efficacy and safety of venlafaxine in poor responders treated with selective serotonin reuptake inhibitors in major depression

作　　者：史天涛 王桂丽[1] 潘烨[1] 王涛[1] 李振江[1] 

机构地区：[1]北京市安康医院,101300

出　　处：《北京医学》2010年第8期666-668,共3页Beijing Medical Journal

摘　　要：目的探讨抑郁症患者经选择性5-羟色胺再摄取抑制剂(SSRIs)治疗无明显疗效换用文拉法辛治疗后的疗效与安全性。方法将经SSRIs治疗6周以上无显著效果的62例抑郁症患者随机分成2组,一组采用文拉法辛治疗(32例),另一组继续用SSRIs治疗并且适当增加剂量,治疗观察8周。应用汉密顿抑郁量表(HAMD-17)和不良反应量表(TESS)评定临床疗效及药物不良反应。结果治疗8周末,文拉法辛组治愈率为25.0%(8/32),SSRIs组治愈率为13.3%(4/30),两组间比较有显著性差异(P<0.05);文拉法辛组与SSRIs组间的TESS评分无显著性差异(1.6±2.4vs.1.7±2.4)。结论抑郁症患者经SSRI治疗无显效时,换用文拉法辛治疗部分患者可获满意疗效且安全性好。Objective To observe the efficacy and tolerability of venlafaxine in major depression patients with poor response treated with SSRIs.Methods Sixty-two major depression patients with non response or partial response to SSRIs for more than 6 weeks were randomly assigned to two groups：one group were treated with venlafaxine （32 patients）, the other group were treated with SSRIs but the dosage was increased.All patients were observed for 8 weeks.The efficacy were evaluated with the Hamilton Depression Rating Scale （HAMD-17）.The side effects were evaluated by Treatment E-mergent Symptom Scale （TESS）.Results The clinical remission rate of the patients treated with venlafaxine was significantly higher than those with SSRI, and the rate of marked improvement was similar in the two groups.No significant differences were found in the side effects between the two groups.Conclusion Major depression patients with poor response to SSRIs can get satisfactory efficacy if venlafaxine is substituted.

关 键 词：抑郁症 选择性5-羟色胺再摄取抑制剂 文拉法辛 

分 类 号：R749.4[医药卫生—神经病学与精神病学]